Charles Newton
Directeur Financier/CFO chez LYELL IMMUNOPHARMA, INC.
Fortune : 119 883 $ au 31/05/2024
Profil
Charles Newton's current job(s) include being an Independent Director at Coherus BioSciences, Inc. since 2022, an Independent Director at 2seventy Bio, Inc. since 2024, and the Chief Financial Officer at Lyell Immunopharma, Inc. since 2021.
Mr. Newton's former job(s) include being a Managing Director at BofA Securities, Inc., a Managing Director at Credit Suisse Group AG from 2010 to 2015, an Independent Director at Carmot Therapeutics, Inc. from 2023 to 2024, and an MD & Head-Western Region Healthcare Investment at Morgan Stanley from 1996 to 2010.
Mr. Newton's education history includes an undergraduate degree from Miami University and an MBA from Tuck School of Business at Dartmouth.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
2SEVENTY BIO, INC.
0,04% | 10/06/2024 | 22 625 ( 0,04% ) | 95 704 $ | 31/05/2024 |
LYELL IMMUNOPHARMA, INC.
0,00% | 31/03/2024 | 8 729 ( 0,00% ) | 24 179 $ | 31/05/2024 |
| 03/06/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Charles Newton
| Sociétés | Poste | Début |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Directeur Financier/CFO | 01/02/2021 |
| COHERUS BIOSCIENCES, INC. | Directeur/Membre du Conseil | 05/05/2022 |
| 2SEVENTY BIO, INC. | Directeur/Membre du Conseil | 20/03/2024 |
Anciens postes connus de Charles Newton
| Sociétés | Poste | Fin |
|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Directeur/Membre du Conseil | 01/01/2024 |
Credit Suisse Group AG /US/
 Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Directeur Général | 01/11/2015 |
| MORGAN STANLEY | Corporate Officer/Principal | 01/09/2010 |
BofA Securities, Inc.
 BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Corporate Officer/Principal | - |
Formation de Charles Newton
| Tuck School of Business at Dartmouth | Masters Business Admin |
| Miami University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| MORGAN STANLEY | Finance |
| 2SEVENTY BIO, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Finance |
BofA Securities, Inc.
BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Finance |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
